Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study
一项多中心、随机、开放标签的3期研究,旨在比较德谷胰岛素/门冬胰岛素生物类似药B01711与原研德谷胰岛素/门冬胰岛素在中国基础胰岛素或预混胰岛素治疗控制不佳的2型糖尿病患者中的疗效和安全性。
期刊:Journal of Diabetes Investigation
影响因子:3
doi:10.1111/jdi.70175
Gao, Leili; Cheng, Zhifeng; Ma, Guoqing; Cai, Xiaojun; Wang, Xiaoyun; Lu, Yibing; Li, Ziling; Li, Wei; Zhao, Shuping; Li, Xuefeng; Song, Chengwei; Gao, Yunming; Geng, Jianlin; Cao, Haiyan; Sun, Jingfang; Ji, Linong